TY - JOUR
T1 - Tourette's disorder
AU - Lyon, Gholson J.
AU - Shprecher, David
AU - Coffey, Barbara
AU - Kurlan, Roger
N1 - Funding Information:
Dr. Shprecher has received salary support from NIH and honoraria from Teva Pharmaceuticals. Drs. Kurlan and Coffey have received research support from Boehringer Ingelheim. Dr. Lyon has received funding from the American Academy of Child and Adolescent Psychiatry (AACAP) and the Tourette Syndrome Association. Dr. Coffey has also received funding from AACAP.
PY - 2010/7
Y1 - 2010/7
N2 - Tourette's disorder (TD) is a common childhood-onset neuropsychiatric disorder characterized by chronic motor and vocal tics. TD frequently occurs with other neuropsychiatric disorders, such as attention deficit hyperactivity disorder (ADHD) and obsessivecompulsive disorder (OCD), and may contribute to reduced quality of life and disability. Currently available treatments to reduce tics are limited by variable clinical response and frequent adverse effects. They include alpha-2 agonists, antipsychotics (first and second generation), tetrabenazine, benzodiazepines, and habit reversal therapy. Some new and emerging (but unproven) treatments are also discussed, including topiramate and dopamine agonists. In addition, there is increasing interest in deep brain stimulation, but this is not yet ready for general use.
AB - Tourette's disorder (TD) is a common childhood-onset neuropsychiatric disorder characterized by chronic motor and vocal tics. TD frequently occurs with other neuropsychiatric disorders, such as attention deficit hyperactivity disorder (ADHD) and obsessivecompulsive disorder (OCD), and may contribute to reduced quality of life and disability. Currently available treatments to reduce tics are limited by variable clinical response and frequent adverse effects. They include alpha-2 agonists, antipsychotics (first and second generation), tetrabenazine, benzodiazepines, and habit reversal therapy. Some new and emerging (but unproven) treatments are also discussed, including topiramate and dopamine agonists. In addition, there is increasing interest in deep brain stimulation, but this is not yet ready for general use.
UR - http://www.scopus.com/inward/record.url?scp=77956395162&partnerID=8YFLogxK
U2 - 10.1007/s11940-010-0073-x
DO - 10.1007/s11940-010-0073-x
M3 - Review article
AN - SCOPUS:77956395162
SN - 1092-8480
VL - 12
SP - 274
EP - 286
JO - Current Treatment Options in Neurology
JF - Current Treatment Options in Neurology
IS - 4
ER -